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non-anthracycline-based chemotherapy and carboplatin-
based versus cisplatin-based chemotherapy were compared. 
This analysis included a retrospective study of response of 
advanced thymic carcinoma to irinotecan and cisplatin in 
our institution.
Results The response rate for the 314 patients from 15 
studies with advanced thymoma, including both prospec-
tive and retrospective data, was 69.4 % [95 % confidence 
interval (CI) 63.1–75.0 %] for platinum with anthracycline-
based chemotherapy and 37.8 % (95 % CI 28.1–48.6 %; 
p < 0.0001) for platinum with non-anthracycline-based 
chemotherapy. The response rates after anthracycline-based 
and non-anthracycline-based chemotherapy for advanced 
thymic carcinoma were similar (41.8 vs. 40.9 %; p < 0.91), 
whereas the response rates after cisplatin-based and carbo-
platin-based chemotherapy for advanced thymic carcinoma 
differed significantly (53.6 vs. 32.8 %; p = 0.0029) in 206 
patients from 10 studies.
Conclusions Platinum with anthracycline-based chem-
otherapy is an optimal combination for advanced thy-
moma. For advanced thymic carcinoma, cisplatin-based 
chemotherapy may be superior to carboplatin-based 
chemotherapy.
Keywords Thymic malignancies · Thymic carcinoma · 
Thymoma · Rare cancer · Chemotherapy
Introduction
Standard chemotherapy for thymomas and thymic carci-
nomas, collectively called thymic malignancies, remains 
undefined because of their rarity. For common cancers, 
standard chemotherapy is determined by means of phase III 
trials that compare experimental chemotherapy with standard 
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chemotherapy. As is common with rare cancers, evaluation 
of chemotherapy for thymomas and thymic carcinomas is 
limited to single-arm phase II trials or retrospective analyses 
involving small numbers of patients. Therefore, the primary 
endpoint for clinical trials regarding thymoma and thymic 
carcinoma is usually response rate and not time to event.
The pathological classification of such tumors has 
been confused because of the transition to modern classi-
fications. At present, the 2004 World Health Organization 
(WHO) classification (Travis et al. 2004) based on clini-
cal prognosis has been agreed by consensus (Huang et al. 
2010). Furthermore, thymoma is a functional immunologi-
cal tumor that retains the immunological characteristics of 
the thymus, whereas thymic carcinoma is associated with 
loss of organotypic status. Thymoma and thymic carci-
noma are rare cancers with an annual incidence of 1.3 to 
3.2/100,000 persons/year (de Jong et al. 2008; Engel et al. 
1999; Engels 2010). Based on the definition of the RARE-
CARE project supported by the European Commission, 
rare cancer has an annual incidence of <6/100,000 persons/
year. Standard chemotherapy for advanced thymoma and 
thymic carcinoma remains controversial because of the 
limited amount of available therapeutic evidence. How-
ever, there is a high level of consensus that the key drugs 
for the treatment of thymoma are anthracycline and cis-
platin (Schmitt and Loehrer 2010), and the chemotherapy 
administered for thymic carcinoma is generally based on 
the chemotherapy administered for thymoma. Furthermore, 
the diagnosis of thymic malignancies is based on modern 
criteria reported by Bernatz et al. (1961), the Levine and 
Rosai classification (Levine and Rosai 1978), the Müller-
Hermelink classification (1986), the 1999 WHO classifica-
tion (Rosai 1999) or the 2004 WHO classification (Travis 
et al. 2004). Recently, prospective and retrospective inves-
tigations of chemotherapy for thymic carcinoma have been 
increasing, but well-designed studies are uncommon and 
the diagnostic reliability regarding thymic carcinoma is not 
always high (Weksler et al. 2013; Zucali et al. 2013).
Consequently, we conducted a pooled analysis to extract 
and compile the data from published reports and to clarify the 
key drugs used for the treatment of advanced thymoma and 
thymic carcinoma. Furthermore, our previously published ret-
rospective data regarding the clinical outcome of cisplatin and 
irinotecan combination chemotherapy for advanced thymic 
carcinoma have been updated (Okuma et al. 2011).
Methods
Selection criteria for literature and our updated data
A systematic search of the PubMed databases was per-
formed to identify all prospective clinical trials and 
retrospective studies involving first-line platinum-based 
chemotherapy for advanced or recurrent thymomas and 
thymic carcinomas. The search included articles from 1990 
to 2013 using the search string “thymoma” OR “thymic 
carcinoma” AND “chemotherapy.” Among these retrieved 
articles, non-English language articles, case reports and 
reviews were excluded. The abstracts of articles of potential 
relevance were reviewed, and articles that were clearly rel-
evant were selected for further analysis. Additionally, stud-
ies presented at the 2013 and 2014 ASCO annual meetings 
were searched to ensure that the most up-to-date articles 
were included in the analysis. Unfortunately, clinical tri-
als for thymoma included patients with thymic carcinoma 
because of the prior criteria for pathological diagnosis. The 
study included all published reports that contained clinical 
outcomes of platinum-based combination chemotherapy 
(cisplatin-based vs. carboplatin-based chemotherapy and 
anthracycline vs. non-anthracycline combination chemo-
therapy) for advanced or recurrent thymoma and thymic 
carcinoma, with some including induction chemotherapy. 
In the studies regarding induction chemotherapy followed 
by surgery or radiotherapy, a small number of patients 
with Masaoka Stage III were included. In such cases, the 
response rate to chemotherapy alone was reported, and the 
time to events was ignored.
We have previously published the outcomes of nine 
cases of cisplatin and irinotecan combination chemother-
apy (Okuma et al. 2011); in addition, we retrospectively 
assessed 12 such cases up until 2013 in the present study 
and combined the data with the above published data, 
including the response rates. A retrospective review was 
performed to collect data on the outcomes of 12 consecu-
tive patients treated with cisplatin and irinotecan chemo-
therapy for advanced thymic carcinoma at Masaoka-Koga 
stage IVa, IVb or recurrent disease. Thymic carcinoma 
was confirmed by hematoxylin and eosin staining and 
immunohistochemistry using CD5 and/or CD117 (c-KIT) 
to exclude other malignant thoracic tumors at the time of 
initial diagnosis. The pathological review was consist-
ently performed by a specialist in thymic malignancies 
(T Hishima). Recurrent disease was defined as disease 
that was not responsive to treatment with curative intent; 
all patients with recurrent disease were chemotherapy 
naïve and underwent chemotherapy with palliative intent. 
Recurrent disease was determined using chest computed 
tomography, magnetic resonance imaging, positron emis-
sion tomography, or bone scanning. Histology was also 
classified according to the 2004 WHO classification, and 
staging was determined using the Masaoka-Koga staging 
system (2010). Data were collected in accordance with the 
International Thymic Malignancy Interest Group (ITMIG) 
standard definitions and policies (Girard et al. 2011). The 
medical records and laboratory data for each patient were 
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retrieved for analysis, and treatments for thymic carcinoma 
were assessed. Progression-free survival (PFS) was defined 
as the time from the first cycle of chemotherapy to the first 
clinical evidence of progressive disease, early discontinua-
tion of treatment or death from any cause. Overall survival 
(OS) was defined as the time from the first cycle of treat-
ment to the time of death from any cause or the last follow-
up. Because of the retrospective nature of the data, these 
end points were chosen to reflect clinical practice. Assess-
ment of response to chemotherapy was achieved using the 
Response Evaluation Criteria in Solid Tumors criteria ver-
sion 1.1 (RECIST 1.1).
Patient selection and statistics
The criteria for the selection included in these published 
reports were patients with cytologically or histologically 
proven advanced or recurrent thymoma or thymic carci-
noma, diagnosed using the modern histological classifica-
tions. Treatment schedule, response, survival assessment 
and statistical analyses were performed to the extent that 
was possible. In all of the identified reports, patients with 
advanced or recurrent thymic malignancies underwent 
platinum-based combination chemotherapy with anthracy-
clines, carboplatin or cisplatin. The treatment response was 
determined using either RECIST criteria version 1.0, ver-
sion 1.1., the WHO criteria, or the European Cooperative 
Oncology Group (ECOG) criteria. The diagnosis was based 
on modern classifications. Time to event (OS or PFS) was 
used as an endpoint in the present study as in the published 
literature; however, the period from the initiation of treat-
ment to the date when disease progression or death was 
observed was used.
The proportion of patients having advanced recurrent 
thymomas or thymic carcinomas, including neuroendocrine 
carcinoma, and the response rates were compared using 
the chi-square test. Statistical significance was defined as 
p < 0.05. Statistical analyses were performed using the 
JMP11 software program (SAS Institute Inc., Cary, NC, 
USA).
The potential for publication bias of the response rates 
in reported studies was assessed using funnel plots, with 
appropriate accuracy intervals.
Results
The process of identifying studies eligible for inclusion 
in our analysis was as follows: first, we reviewed 57 full 
articles from 393 published studies and meeting abstracts 
related to thymomas and excluded 208 case reports and 
review articles. Of the total 160 published articles and 
meeting abstracts on thymic carcinoma, we reviewed 78 
full articles and excluded 82 case reports and review arti-
cles. Of these, 15 studies met the inclusion criteria.
Characteristics of the selected studies
The preliminary analysis encompassed 15 studies involv-
ing a total of 314 patients with advanced or recurrent thy-
moma who were treated using platinum with or without 
anthracycline chemotherapy. In these studies, thymic carci-
noma was included because it was considered as being type 
C thymoma. The studies included ten prospective stud-
ies and five retrospective studies (Table 1). In addition, a 
total of 206 patients with advanced thymic carcinoma were 
included in a pooled analysis of platinum with or with-
out anthracycline chemotherapy in ten studies, consisting 
of four prospective studies and six retrospective studies 
(Tables 2, 3).
A total of 12 patients who were treated with cisplatin 
and irinotecan combination chemotherapy as palliative-
intent chemotherapy were also evaluated. Nine partial 
responses (75.0 %) and two stable diseases [16.7 %; total 
disease control was observed in 11 patients (91.7 %)] were 
recorded. One patient had progressive disease. There were 
no complete responders. The median PFS was 7.4 months 
[95 % confidence interval (CI) 2.2–9.2 months), while the 
median OS was 52.4 months (95 % CI 9.4–114.2 months). 
The 1- and 2-year survival rates based on the Kaplan–
Meier analysis were 88.9 and 66.7 %, respectively.
Response to platinum-based chemotherapy in advanced 
thymoma and thymic carcinoma
The response rate of thymoma to anthracycline-based 
chemotherapy was 69.4 % (95 % CI 63.1–75.0 %) and 
37.8 % (95 % CI 28.1–48.6 %) to non-anthracycline-based 
chemotherapy. The difference in the response rates between 
anthracycline-based chemotherapy and non-anthracycline-
based chemotherapy with cisplatin was statistically signifi-
cant (χ2 test; p < 0.0001). The response rates of thymic car-
cinoma to anthracycline-based chemotherapy were 41.8 % 
(95 % CI 31.5–52.8 %) and 40.9 % (95 % CI 32.8–49.6 %) 
to non-anthracycline-based chemotherapy (Table 2); there 
was no significant difference in the response rates (χ2 test; 
p < 0.82). The response rates of thymic carcinoma were 
53.6 % (95 % CI 43.0–63.8 %) to cisplatin-based chemo-
therapy and 32.8 % (95 % CI 25.1–41.5 %) to carbopl-
atin-based chemotherapy (Table 3); the difference in the 
response rates was significant (χ2 test; p = 0.0029).
Publication bias
Potential publication bias was assessed using funnel plots 
with response rates as the outcome. The funnel plots were 
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basically symmetrical for each of the regimen categories 
(Fig. 1), indicating a lack of publication bias. However, 
in category (A) for anthracycline-based chemotherapy for 
thymoma, two outliers (Fornasiero et al. 1991; Kawashima 
et al. 2013) from the 95 % tolerance limit were observed. 
We repeated our analyses excluding these two studies, the 
response rate in the anthracycline regimen for thymoma 
was 59.8 %, and the chi-square test still demonstrated a sig-
nificant difference (p < 0.0001).
Discussion
Our pooled analysis demonstrated that anthracycline-based 
chemotherapies involving cisplatin appeared to play a 
key role in improving the response rate of advanced thy-
moma. In addition, the response rate of advanced thymic 
carcinoma was significantly higher with cisplatin-based 
chemotherapy than with carboplatin-based chemotherapy; 
however, no significant difference in response rates was 
found between anthracycline-containing regimens and non-
anthracycline-containing regimens using platinum-based 
chemotherapies.
Platinum-based chemotherapy in combination with 
anthracycline has been suggested as the key regimen for 
the treatment of advanced thymoma and thymic carcinoma. 
However, only a small number of patients have been enrolled 
in phase II trials or retrospective studies regarding the evalu-
ation of therapeutic efficacy. Moreover, until the advent of 
the 2004 WHO classification, thymoma and thymic carci-
noma were not clearly distinguished. However, recent stud-
ies have revealed these two carcinomas are different clinical 
entities in terms of biobehavior and biomarkers (Monica 
et al. 2013) and clinical outcomes. Therefore, the efficacy 
of chemotherapy may differ as well; however, the utility of 
chemotherapy itself remains unclear because none of the tri-
als compared chemotherapy with best supportive care. The 
present study focused on clarifying the key drugs regarding 
the treatment of advanced thymic carcinoma. Einhorn’s pro-
tocol, which consists of a cisplatin- and anthracycline-based 
triplet or quartet regimen, such as ADOC (cisplatin, doxoru-
bicin, vincristine and cyclophosphamide) (Fornasiero et al. 
1991) or PAC (cisplatin, cyclophosphamide and adriamycin) 
(Loehrer et al. 1997), is conventionally used for invasive thy-
moma. The response rates of first-line chemotherapies for 
thymoma have been compared in phase II trials, and cisplatin 
Table 1  Unified response rates of advanced thymoma patients treated with anthracycline-based or non-anthracycline-based chemotherapy regi-
mens
G prospective multicenter group phase II trial, S single-center experience, mos months, RR objective response rate, ADOC adriamycin, cis-
platin, vincristine and cyclophosphamide, PAC cisplatin, adriamycin and cyclophosphamide, PAE cisplatin, adriamycin and etoposide, 
CAMP PAC = cisplatin, adriamycin, methylprednisolone and cyclophosphamide, CODE adriamycin, cisplatin, vincristine and etoposide, 
PE cisplatin and etoposide, VIP vincristine, ifosfamide and cisplatin, CarboPTX carboplatin and paclitaxel
a
 Including four patients with thymic carcinoma in the VIP trial
Regimen Author, year Study design Stage No. of patients Responders RR PFS OS
Anthracycline-containing regimens
ADOC Fornasiero et al. (1991) S III/IVa/IVb 37 34 91.8 % 12 mos 15 mos
PAC Loehrer et al. (1994) G IV 29 15 51.7 % 11.8 mos 37.7 mos
PAC (+XRT) Loehrer et al. (1997) G III 23 16 69.6 % – 93 mos
ADOC Rea et al. (1993) S III/IVa 16 12 75.0 % – 66 mos
ADOC Berruti et al. (1999) S III/IVa 16 13 81.3 % 33.2 mos 47.5 mos
PAC Kim et al. (2004) G III/IVa/IVb 22 17 77.3 % – –
PAE (+XRT) Lucchi et al. (2006) S III/IVA 30 22 73.3 % – –
CAMP Yokoi et al. (2007) S IVa/IVb 14 13 92.9 % – –
Dose-dense CODE Kunitoh et al. (2009) G IVa/IVb 27 16 59.3 % 0.79 year 6.1 year
CarboAMR Kawashima et al. (2013) G Invasive 18 3 16.7 % 7.6 mos Not reached
Total 232 161 69.4 %
Non-anthracycline-containing regimens
PE Giaccone et al. (1996) G III/IV/rec 16 9 56 % 2.2 year 4.3 year
VIP Loehrer et al. (2001) G III/IVa/IVb 20 7 35 % 11.9 mos 31.6 mos
VIP Grassin et al. (2011) G IIIB/IVA/IVB 16a 4a 25 %a 13.1 mos Not reached
CarboPTX Takeda et al. (2013) G III/IVa/IVb 21 6 42.9 % 16.7 mos Not reached
CDDP/DTX Park et al. (2013) G III/IVa/IVb 9 5 55.6 % – –
Total 82 31 37.8 %
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and anthracycline have been considered the key drugs. Actu-
ally, cisplatin and anthracycline-containing regimens for thy-
moma have achieved significantly higher response rates than 
non-anthracycline regimens (Table 1). A dose-dense chemo-
therapy regimen for thymoma has not always improved effi-
cacy (Kunitoh et al. 2009).
Table 2  Unified response rates of advanced thymic carcinoma patients treated with anthracycline-based or non-anthracycline-based chemo-
therapy regimens
G prospective multicenter group phase II trial, S single-center experience, RR response rate, PFS progression-free survival, OS overall survival, 
ADOC adriamycin, cisplatin, vincristine and cyclophosphamide, CODE adriamycin, cisplatin, vincristine and etoposide, CarboAMR carboplatin 
and amrubicin, CarboPTX carboplatin and paclitaxel, CDDP/CPT-11 cisplatin and irinotecan, CDDP/DTX cisplatin/docetaxel
a
 The subset for thymic carcinoma
b
 The accrual criteria were defined as “invasive” thymoma or thymic carcinoma, not according to any defined staging system. The chemothera-
peutic setting was within the two previous regimens
Regimen Author, year Study design Stage No. of patients Responders RR PFS (mos) MST (mos)
Anthracycline-based chemotherapy
ADOC Agatsuma et al. (2011) S IVa/IVb 34 17 50 % N/A 21.3
CODE Yoh et al. (2003) S III/IVa/IVb 12 5 42 % 5.6 46
CarboAMRa Kawashima et al. (2013) G Invasivea 33 11 30 % 7.6 27.3
Total 79 33 41.8 %
Non-anthracycline-based chemotherapy
VIP Grassin et al. (2011) S III/IVa/IVb 8 2 25 % – –
CarboPTX Lemma et al. (2011) G III/IVa/IVb 23 5 21.7 % 5.0 20.0
CarboPTX Igawa et al. (2010) S IVa/IVb 11 4 36 % 7.9 22.7
CarboPTX Takeda et al. (2013) G III/IVa/IVb 39 14 35.9 % 7.52 Not reached
CarboPTX Furugen et al. (2011) S IVa/IVb/rec 16 6 37.5 % 8.6 49.4
CDDP/DTXb Park et al. (2013) G III/IVa 18 12 66.7 % – –
CDDP/CPT-11 Present study S IVa/IVb/rec 12 9 75.0 % 7.4 52.4
Total 127 52 40.9 %
Table 3  Unified response rates of advanced thymic carcinoma patients treated with cisplatin-based or carboplatin-based chemotherapy regimens
G prospective multicenter group phase II trial, S single-center experience, RR response rate, PFS progression-free survival, OS overall survival, 
ADOC adriamycin, cisplatin, vincristine and cyclophosphamide, CODE adriamycin, cisplatin, vincristine and etoposide, CarboAMR carboplatin 
and amrubicin, CarboPTX carboplatin and paclitaxel, CDDP/CPT-11 cisplatin and irinotecan, CDDP/DTX cisplatin/docetaxel
a
 The subset for thymic carcinoma
Regimen Author, year Study design Stage No. of patients Responders RR PFS (mos) MST (mos)
Cisplatin-based chemotherapy
ADOC Agatsuma et al. (2011) S IVa/IVb 34 17 50 % N/A 21.3
CODE Yoh et al. (2003) S III/IVa/IVb 12 5 42 % 5.6 46
VIP Grassin et al. (2011) S III/IVa/IVb 8 2 25 % – –
CDDP/DTXa Park et al. (2013) G III/IVa 18 12 66.7 % – –
CDDP/CPT-11 Present study S IVa/IVb/rec 12 9 75.0 % 7.4 52.4
Total 84 45 53.6 %
Carboplatin-based chemotherapy
CarboPTX Lemma et al. (2011) G III/IVa/IVb 23 5 21.7 % 5.0 20.0
CarboPTX Igawa et al. (2010) S IVa/IVb 11 4 36 % 7.9 22.7
CarboPTX Takeda et al. (2013) G III/IVa/IVb 39 14 35.9 % 7.52 Not reached
CarboPTX Furugen et al. (2011) S IVa/IVb/rec 16 6 37.5 % 8.6 49.4
CarboAMRa Kawashima et al. (2013) G Invasivea 33 11 30 % 7.6 27.3
Total 122 40 32.8 %
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Chemotherapy regimens designed for the treatment of 
thymoma have also been used for thymic carcinoma. Only 
two prospective studies have assessed carboplatin and 
paclitaxel as palliative-intent chemotherapy for advanced 
stage disease, and one study has assessed induction chemo-
therapy (Lemma et al. 2011; Park et al. 2013; Takeda et al. 
2013). The response rate achieved with carboplatin and 
paclitaxel was 30–40 %, whereas induction chemotherapy 
followed by curative-intent treatments involving cispl-
atin and docetaxel combination chemotherapy achieved a 
66.7 % response rate in the subset of patients with thymic 
carcinoma (Park et al. 2013). Carboplatin-based chemo-
therapy is broadly used as a combination regimen with 
less nausea and vomiting or nephrotoxicity than that was 
reported in the early 2000s. However, more effective anti-
emetic agents have recently become available, and conse-
quently, cisplatin-based combination chemotherapy has 
become more easily available. Therefore, further clinical 
trials should evaluate cisplatin-based chemotherapy for 
thymic carcinoma. At present, any platinum-based dou-
blet chemotherapy seems appropriate with the view of 
maximizing the PFS of patients with thymic carcinoma 
(Table 2).
The present analysis updated the data regarding the 
clinical outcome of patients with advanced thymic carci-
noma treated using cisplatin and irinotecan, including both 
squamous cell carcinoma and neuroendocrine carcinoma 
subtypes, with a response rate of 66.7 %. In the WJTOG 
4207L trial, half of the patients were re-diagnosed as 
having neuroendocrine carcinoma. In thymic squamous 
cell carcinoma, positivity for biomarkers of neuroendo-
crine carcinoma, such as synaptophysin, neuron-specific 
enolase, chromogranin A and CD57, has been previously 
documented (Lauriola et al. 1998). Cisplatin and irinotecan 
combination chemotherapy will be one of the choices for 
treatment as it covers a broad spectrum of subtypes as has 
been proven to be the case in lung cancer (Noda et al. 2002; 
Ohe et al. 2007).
The accurate diagnosis of thymoma and thymic car-
cinoma has recently been discussed as being crucial with 
regard to the proof of the efficacy of chemotherapy for 
these rare cancers. Mismatched diagnoses have been sus-
pected in another clinical trial involving rare cancers, the 
multi-institutional clinical trial regarding imatinib treat-
ment for c-KIT or platelet-derived growth factor receptor 
(PDGFR)-positive sarcoma (Sugiura et al. 2010). In this 
trial, the concordance rate between the trial sites and the 
central review involving immunohistochemical staining 
was 63.3 %. The results of such studies must be carefully 
interpreted because a few diagnostic errors in phase II stud-
ies with small sample sizes will result in a lack of power 
to test statistical hypotheses. Investigators who plan clinical 
trials involving thymic malignancies should incorporate a 
central review by reliable pathologists who have experience 
with thymic malignancies. Large-scale regional databases 
are being established in the USA, Europe and Japan as the 
first step to curative treatment for thymoma and thymic car-
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Fig. 1  Funnel plots using response rates as an outcome for a, b thymoma and c–f thymic carcinoma in each chemotherapy category (anthracy-
cline-based vs. non-anthracycline-based and cisplatin-based vs. carboplatin-based)
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be a role model for rare diseases, and the process of estab-
lishing databases will help to clarify diagnostic problems. 
In fact, the WJTOG 4207L trial demonstrated that in 25 % 
of patients the diagnosis differed between local and cen-
tral review(Takeda et al. 2013). In thymic malignancies, 
the reproducibility of pathological diagnosis was exam-
ined in an Italian study (Zucali et al. 2013). Clinical tri-
als of rare cancers are limited in that only small numbers 
of patients can be enrolled. Consequently, misdiagnosis 
of some patients will invalidate the results of the clinical 
trial. In common cancers, multi-institutional clinical trials 
provide a higher level of evidence than trials incorporat-
ing a single or a few institutions. However, the opposite is 
potentially true of clinical trials involving rare cancers. Up 
to 20 % of thymic malignancies are difficult to diagnose 
and are termed “borderline.” In fact, diagnostic agreement 
regarding surgical specimens was low (Zucali et al. 2013). 
In advanced thymic carcinoma, clinicians should note that 
the patients are usually diagnosed based on the examina-
tion of needle biopsy specimens. As this previous study 
demonstrated, diagnostic differences occurred among type 
A thymoma and thymic carcinoma patients (Zucali et al. 
2013). Moreover, differentiating between type B thymoma 
and thymic carcinoma has been difficult for pathologists. 
In patients with type B3 thymoma, previously called “well-
differentiated thymic carcinoma,” the median survival 
time was 99 months (95 % CI 63.4–134.6), whereas it was 
48 months (95 % CI 38.4–94.1; p  < 0.001) in patients with 
thymic carcinoma (Gao et al. 2013). Since the key drugs 
used for the treatment of thymoma and thymic carcinoma 
can differ, it is important to have the correct diagnosis to 
choose the optimal therapy.
The current study had a number of limitations. They 
included the use of mixed data from prospective and ret-
rospective studies with different criteria, including varia-
tions in the precise histological classification of subtypes, 
staging or assessment criteria. Moreover, detailed patient 
characteristics could not be completely extracted. However, 
this is a common limitation in such studies involving small 
numbers of patients with rare cancers. Furthermore, it was 
not possible to include time-to-event endpoints, such as 
progression-free survival and overall survival, in the analy-
sis since individual data regarding chemotherapy for thy-
momas and thymic carcinomas were not available. It is rec-
ommended that the efficacy of chemotherapy be evaluated 
using time to event, and not only tumor response endpoints 
(Anderson et al. 1983). Therefore, an optimal chemother-
apy regimen for advanced thymomas and thymic carci-
nomas has still not been established. Medical oncologists 
should choose the chemotherapy for thymoma and thymic 
carcinoma based on the treatment setting and/or consid-
eration of the side effects of the chemotherapy. Moreo-
ver, there exists a potential publication. For instance, two 
published studies lay outside the 95 % tolerance limit of the 
pooled estimate. The reasons for this may be attributed to 
the following: (1) The study by Fornasiero et al., which was 
the higher outlier, was the oldest study performed at a sin-
gle institution. However, prospective studies demonstrated 
a similar response rate for thymoma (75 and 81.3 %); (2) 
the study by Kawashima et al. was the only study using 
amrubicin as anthracycline. Amrubicin is the only totally 
chemically synthesized anthracycline and commonly inhib-
its topoisomerase II enzyme; however, the other mecha-
nisms of action for its anticancer activity are speculated to 
differ as it has weaker DNA intercalation activity than the 
other anthracycline agents (Noguchi et al. 2005). There-
fore, amrubicin may not be the best drug choice for thymic 
malignancies.
In conclusion, the present pooled analysis demonstrated 
that platinum with anthracycline-based chemotherapy is 
an optimal combination for the treatment of advanced 
thymoma. For advanced thymic carcinoma, cisplatin-
based chemotherapy may be superior to carboplatin-based 
chemotherapy.
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